Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel A Craven

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Proteomics. Clinical Applications|November 18, 2014
An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysisSophie Hepburn, David A Cairns, David Jackson, et al.
British Journal of Haematology|November 6, 2007
Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myelomaKaren S Rees-Unwin, Rachel A Craven, Emma Davenport, et al.
Proteomics|June 2, 2006
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinomaRachel A Craven, Sarah Hanrahan, Nick Totty, et al.
Proteomics|September 28, 2004
Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell linesRachel A Craven, Anthea J Stanley, Sarah Hanrahan, et al.
International Journal of Oncology|August 24, 2013
VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancerVassilis Aggelis, Rachel A Craven, Jianhe Peng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAlison C Young, Rachel A Craven, Dena Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancerDavid Jackson, Rachel A Craven, Richard C Hutson, et al.
British Journal of Cancer|May 12, 2020
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasionNick Hornigold, Karen R Dunn, Rachel A Craven, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Proteomics. Clinical Applications|November 18, 2014
An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysisSophie Hepburn, David A Cairns, David Jackson, et al.
British Journal of Haematology|November 6, 2007
Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myelomaKaren S Rees-Unwin, Rachel A Craven, Emma Davenport, et al.
Proteomics|June 2, 2006
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinomaRachel A Craven, Sarah Hanrahan, Nick Totty, et al.
Proteomics|September 28, 2004
Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell linesRachel A Craven, Anthea J Stanley, Sarah Hanrahan, et al.
International Journal of Oncology|August 24, 2013
VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancerVassilis Aggelis, Rachel A Craven, Jianhe Peng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAlison C Young, Rachel A Craven, Dena Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancerDavid Jackson, Rachel A Craven, Richard C Hutson, et al.
British Journal of Cancer|May 12, 2020
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasionNick Hornigold, Karen R Dunn, Rachel A Craven, et al.
Pageof 3